The study examined the relationship between the drug maker Eli Lilly and 161 health advocacy groups who collected payments from the company. Comparing Eli Lilly’s payment disclosure with the groups’ disclosures, the study found that only 25 percent of the groups acknowledged Lilly’s support on their public websites, and only 10 percent disclosed Lilly as the sponsor of a specific grant.
The researchers recommended expanding the Physician Payment Sunshine Act to require drug and medical device companies to report these payments. They also said federal tax regulations should force nonprofit health advocacy groups to list industry donors and sums on their tax returns.
Read the New York Times report on health advocacy groups.
Read more on drug manufacturers:
–6 Predictions on Device Market Growth in the Next Five Years
–Study: Extending Clinical Data Could Raise Drug Costs, Life Expectancy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.